الفهرس 
Title: Expression of CYP3A5*3 & CYP1A1*2C polymorphism in adult patient with acute myeloid leukaemia & relation with clinical response
IndexOnly 14 pages are availabe for public view
 |  | from | 186 |  |  |
| | | from | 186 | | |
Abstract
Background: Genetic variations are one of the important factors in the development of acute leukemia. Molecular studies have proved that genetic polymorphism of metabolic enzymes influence the risk of a variety of tumors including leukemia. Cytochrome P450 (CYP) enzyme catalyzes the phase I metabolism reaction which metabolize endogenous and exogenous DNA-reactive chemical compounds and xenobiotics which could induce genotoxicity and increase the risk for leukemia. Aim of the study: To detect the frequency of CYP3A5*3 and CYP1A1*2C polymorphisms in Egyptian acute myeloid leukemia (AML) patients and to determine the role of genotypes variants as a risk factor for developing leukemia. Patient and Method: Detection of CYP3A5*3 and CYP1A1*2C polymorphisms using PCR-RFLP method in 70 newly diagnosed AML cases and 30 age and sex comparable healthy controls. Results: we found that CYP3A5*3 polymorphism (3/3) and (1/3) genotypes were significantly elevated in AML group compared to control group (p=0.002). However, no statistical significant differences were found between patients and control group as regard CYP1A1*2C polymorphism. Conclusion: Results suggest that Egyptians carrying CYP3A5*3 polymorphism might have an increased risk of AML emphasizing the significance of effective phase I detoxification in carcinogenesis